NSCLC cell lines PC-9 and HCC827, which were sensitive to gefitinib, expressed undetectable amounts of FGF3, FGF4, FGF19, and low levels of CCND1 (Figure 1A). This evidence concerns the gene FGF4 and non-small cell lung carcinoma.